

INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP, HOWARD\_DENDRITIC\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP

ZAK\_PBMK\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_AD5\_NAB\_TITERS\_GT\_200\_VS\_LTE\_200\_1DY\_DN, ZAK\_PBMK\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_AD5\_NAB\_TITERS\_GT\_200\_VS\_LTE\_200\_1DY\_DN  
FRANCO\_BLOOD\_SANOFI\_PASTEUR\_SA\_INACTIVATED\_INFLUENZA\_VACCINE\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_AGE\_18\_40YO\_1DY\_POSITIVE, FRANCO\_BLOOD\_SANOFI\_PASTEUR\_SA\_INACTIVATED\_INFLUENZA\_VACCINE\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_AGE\_18\_40YO\_1DY\_POSITIVE  
MATSUMIYA\_PBMK\_MODIFIED\_VACCINIA\_ANKARA\_VACCINE\_AGE\_18\_55YO\_2DY\_UP, MATSUMIYA\_PBMK\_MODIFIED\_VACCINIA\_ANKARA\_VACCINE\_AGE\_18\_55YO\_2DY\_UP  
FLETCHER\_PBMK\_BCG\_10W\_INFANT\_BCG\_STIMULATED\_VS\_UNSTIMULATED\_10W\_UP, FLETCHER\_PBMK\_BCG\_10W\_INFANT\_BCG\_STIMULATED\_VS\_UNSTIMULATED\_10W\_UP  
FLETCHER\_PBMK\_BCG\_10W\_INFANT\_PPD\_STIMULATED\_VS\_UNSTIMULATED\_10W\_UP, FLETCHER\_PBMK\_BCG\_10W\_INFANT\_PPD\_STIMULATED\_VS\_UNSTIMULATED\_10W\_UP  
ZAK\_PBMK\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_3DY\_UP, ZAK\_PBMK\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_3DY\_UP  
SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_32YO\_2\_TO\_4DY\_UP, SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_32YO\_2\_TO\_4DY\_UP  
GAUCHER\_PBMK\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_10DY\_UP, GAUCHER\_PBMK\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_10DY\_UP  
ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_NAIVE\_NOT\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP, ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_NAIVE\_NOT\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP  
WEINBERGER\_BLOOD\_TWINRIX\_AGE\_20\_40\_AND\_60\_84YO\_CORRELATED\_WITH\_ANTI\_HB5\_CONC\_PRIMARY\_VACC\_1DY\_SIGNIFICANT, WEINBERGER\_BLOOD\_TWINRIX\_AGE\_20\_40\_AND\_60\_84YO\_CORRELATED\_WITH\_ANTI\_HB5\_CONC\_PRIMARY\_VACC\_1DY\_SIGNIFICANT  
LI\_PBMK\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_18\_45YO\_3DY\_UP, LI\_PBMK\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_18\_45YO\_3DY\_UP  
QUEREC\_PBMK\_YF\_17D\_VACCINE\_AGE\_18\_45YO\_3DY\_UP, QUEREC\_PBMK\_YF\_17D\_VACCINE\_AGE\_18\_45YO\_3DY\_UP  
QUEREC\_PBMK\_YF\_17D\_VACCINE\_AGE\_18\_45YO\_7DY\_UP, QUEREC\_PBMK\_YF\_17D\_VACCINE\_AGE\_18\_45YO\_7DY\_UP  
SOBOLEV\_PBMK\_PANDEMRIX\_AGE\_18\_64YO\_1DY\_UP, SOBOLEV\_PBMK\_PANDEMRIX\_AGE\_18\_64YO\_1DY\_UP  
HOWARD\_T\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP, HOWARD\_T\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP  
NAKAYA\_PBMK\_FLUMIST\_AGE\_18\_50YO\_3DY\_IFN\_SUBSET\_UP, NAKAYA\_PBMK\_FLUMIST\_AGE\_18\_50YO\_3DY\_IFN\_SUBSET\_UP  
NAKAYA\_PBMK\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_ATIV\_UP, NAKAYA\_PBMK\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_ATIV\_UP  
ERWIN\_COHEN\_BLOOD\_VACCINE\_TC\_83\_AGE\_23\_48YO\_VACCINATED\_VS\_CONTROL\_7DY\_UP, ERWIN\_COHEN\_BLOOD\_VACCINE\_TC\_83\_AGE\_23\_48YO\_VACCINATED\_VS\_CONTROL\_7DY\_UP  
ERWIN\_COHEN\_BLOOD\_TC\_83\_AGE\_23\_48YO\_VACCINATED\_VS\_CONTROL\_2DY\_UP, ERWIN\_COHEN\_BLOOD\_TC\_83\_AGE\_23\_48YO\_VACCINATED\_VS\_CONTROL\_2DY\_UP  
HOWARD\_NEUTROPHIL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_3DY\_UP, HOWARD\_NEUTROPHIL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_3DY\_UP  
PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGE\_6HR\_TOP\_30\_DEG\_UP, PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGE\_6HR\_TOP\_30\_DEG\_UP  
GAUCHER\_PBMK\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_60DY\_UP, GAUCHER\_PBMK\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_60DY\_UP  
HOEK\_NEUTROPHIL\_2011\_2012\_TIV\_ADULT\_7DY\_DN, HOEK\_NEUTROPHIL\_2011\_2012\_TIV\_ADULT\_7DY\_DN  
HOEK\_PBMK\_INACTIVATED\_INFLUENZA\_ADULT\_7DY\_DN, HOEK\_PBMK\_INACTIVATED\_INFLUENZA\_ADULT\_7DY\_DN  
LI\_PBMK\_MENACTRA\_AGE\_18\_45YO\_ANTI\_POLYSACCHARIDE\_ANTIBODY\_CORRELATION\_PROFILE\_3DY\_DN, LI\_PBMK\_MENACTRA\_AGE\_18\_45YO\_ANTI\_POLYSACCHARIDE\_ANTIBODY\_CORRELATION\_PROFILE\_3DY\_DN  
HOEK\_NEUTROPHIL\_2011\_2012\_TIV\_ADULT\_1DY\_UP, HOEK\_NEUTROPHIL\_2011\_2012\_TIV\_ADULT\_1DY\_UP  
VAN\_DEN\_BIGGELAAR\_PBMK\_PREVNAR\_9MO\_INFANT\_STIMULATED\_VS\_UNSTIMULATED\_8MO\_UP, VAN\_DEN\_BIGGELAAR\_PBMK\_PREVNAR\_9MO\_INFANT\_STIMULATED\_VS\_UNSTIMULATED\_8MO\_UP  
ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_NON\_RESPONDERS\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP, ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_NON\_RESPONDERS\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP  
SCHERER\_PBMK\_YF\_VAX\_AGE\_18\_40YO\_JOINT\_TO\_VACCINIA\_AND\_YELLOW\_FEVER\_UP, SCHERER\_PBMK\_YF\_VAX\_AGE\_18\_40YO\_JOINT\_TO\_VACCINIA\_AND\_YELLOW\_FEVER\_UP  
SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_40YO\_JOINT\_TO\_VACCINIA\_AND\_YELLOW\_FEVER\_UP, SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_40YO\_JOINT\_TO\_VACCINIA\_AND\_YELLOW\_FEVER\_UP  
NAKAYA\_PBMK\_FLUAD\_IMUVAC\_MALE\_AGE\_14\_27YO\_CORRELATED\_WITH\_HAI\_RESPONSE\_MF59\_ADJUVANTED\_NON\_1DY\_GENES\_IN\_BTMM75\_POSITIVE, NAKAYA\_PBMK\_FLUAD\_IMUVAC\_MALE\_AGE\_14\_27YO\_CORRELATED\_WITH\_HAI\_RESPONSE\_MF59\_ADJUVANTED\_NON\_1DY\_GENES\_IN\_BTMM75\_POSITIVE  
HOWARD\_NK\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP, HOWARD\_NK\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_UP  
HOWARD\_DENDRITIC\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_3DY\_UP, HOWARD\_DENDRITIC\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_3DY\_UP  
ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_RESPONDERS\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP, ERWIN\_COHEN\_PBMK\_TC\_83\_AGE\_18\_45YO\_RESPONDERS\_PREVIOUSLY\_IMMUNIZED\_24HR\_DEG\_CANONICAL\_PATHWAY\_MEMBERS\_UP  
PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGED\_POST\_VACCINATION\_VS\_UNCHALLENGED\_72HR\_TOP\_30\_DEG\_UP, PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGED\_POST\_VACCINATION\_VS\_UNCHALLENGED\_72HR\_TOP\_30\_DEG\_UP  
NAKAYA\_PBMK\_IMUVAC\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0DY\_PREIMM\_TIV\_UP, NAKAYA\_PBMK\_IMUVAC\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0DY\_PREIMM\_TIV\_UP  
KAZMIN\_PBMK\_P\_FALCIPARUM\_RTSS\_AS01\_UNKN\_AGE\_IMM\_WITH\_ARR\_VS\_IMM\_BY\_RRR\_PRIMARY\_IMMUNIZ\_WITH\_RECOMB\_ADENOVIRUS\_35\_1DY\_UP, KAZMIN\_PBMK\_P\_FALCIPARUM\_RTSS\_AS01\_UNKN\_AGE\_IMM\_WITH\_ARR\_VS\_IMM\_BY\_RRR\_PRIMARY\_IMMUNIZ\_WITH\_RECOMB\_ADENOVIRUS\_35\_1DY\_UP  
SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_40YO\_5\_TO\_7DY\_UP, SCHERER\_PBMK\_APSV\_WETVAX\_AGE\_18\_40YO\_5\_TO\_7DY\_UP  
BUCASAS\_PBMK\_FLUARIX\_FLUVIRIN\_CAUCASIAN\_MALE\_AGE\_18\_40YO\_HIGH\_RESPONDERS\_1DY\_TOP\_FUNCTIONAL\_NETWORK\_POSITIVE, BUCASAS\_PBMK\_FLUARIX\_FLUVIRIN\_CAUCASIAN\_MALE\_AGE\_18\_40YO\_HIGH\_RESPONDERS\_1DY\_TOP\_FUNCTIONAL\_NETWORK\_POSITIVE  
QIU\_PBMK\_HEPTATITIS\_B\_SURFACE\_ANTIGEN\_AGE\_UNDER50\_NON\_RESPONDERS\_VS\_RESPONDERS\_35DY\_UP, QIU\_PBMK\_HEPTATITIS\_B\_SURFACE\_ANTIGEN\_AGE\_UNDER50\_NON\_RESPONDERS\_VS\_RESPONDERS\_35DY\_UP